Literature DB >> 33095378

The Effects of Supplement Therapy on HCV-Related HCC: a Case Report of a Patient Who Had Undergone TACE for Six Times.

Khin Maung Lwin1, Yamin Kyaw Swar Dee2, Ye Htut Linn3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33095378     DOI： 10.1007/s12029-020-00540-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  28 in total

Review 1.  Local-regional treatment of hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Laura Crocetti
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

2.  Silibinin efficacy against human hepatocellular carcinoma.

Authors:  Leyon Varghese; Chapla Agarwal; Alpana Tyagi; Rana P Singh; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

Review 3.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

4.  Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats.

Authors:  Gopalakrishnan Ramakrishnan; Hanumantha Rao Balaji Raghavendran; Radhakrishnan Vinodhkumar; Thiruvengadam Devaki
Journal:  Chem Biol Interact       Date:  2006-03-22       Impact factor: 5.192

5.  Effects of silymarin and silymarin-doxorubicin applications on telomerase activity of human hepatocellular carcinoma cell line HepG2.

Authors:  Erkan Yurtcu; Ozlem Darcansoy Iseri; Feride Iffet Sahin
Journal:  J BUON       Date:  2015 Mar-Apr       Impact factor: 2.533

6.  Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma.

Authors:  N Nagasue; M Uchida; Y Makino; Y Takemoto; A Yamanoi; T Hayashi; Y C Chang; H Kohno; T Nakamura; H Yukaya
Journal:  Gastroenterology       Date:  1993-08       Impact factor: 22.682

7.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

8.  Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.

Authors:  S Kawai; J Okamura; M Ogawa; Y Ohashi; M Tani; J Inoue; Y Kawarada; M Kusano; Y Kubo; C Kuroda
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells.

Authors:  G Ramakrishnan; L Lo Muzio; C M Elinos-Báez; S Jagan; T A Augustine; S Kamaraj; P Anandakumar; T Devaki
Journal:  Cell Prolif       Date:  2009-04       Impact factor: 6.831

10.  Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells.

Authors:  Song Zhang; Yang Yang; Zhenxing Liang; Weixun Duan; Jian Yang; Juanjuan Yan; Ning Wang; Wenqiang Feng; Meiling Ding; Yongzhan Nie; Zhenxiao Jin
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240
View more
  1 in total

1.  Construction and Validation of Prediction Model of Severe Abdominal Pain Post-Transarterial Chemoembolization in Patients with HBV-Associated Primary Liver Cancer.

Authors:  Yaobo Yang; Sipan Chen; Zhaoyong Yan; Yang Jiao; Xiang Yan; Yulong Li
Journal:  Comput Math Methods Med       Date:  2022-07-30       Impact factor: 2.809
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.